Peter Loftus

Peter Loftus is a reporter for The Wall Street Journal in Philadelphia covering the pharmaceutical and medical-device industries. He has written about Covid-19 vaccines, advances in cancer treatments, drug shortages and the use of mobile devices in healthcare. Peter is the author of "The Messenger: Moderna, the Vaccine, and the Business Gamble That Changed the World," published in 2021 by Harvard Business Review Press. In 2016, he was part of a Journal team that was a finalist for the Pulitzer Prize in explanatory reporting for a series of articles about rising prescription drug prices. Before joining The Wall Street Journal in 2013, Peter worked as a reporter for Dow Jones Newswires since 1997 covering the pharmaceutical and technology industries. He previously worked as a courthouse reporter at the Reporter newspaper in Lansdale, Pa.

Biography:  https://www.wsj.com/news/author/peter-loftus

54%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author has a mixed reputation for journalistic standards. It is advisable to fact-check, scrutinize for bias, and check for conflicts of interest before relying on the author's reporting.

Bias

75%

Examples:

  • The author has a bias towards the pharmaceutical industry as they have written about advances in cancer treatments and drug shortages.

Conflicts of Interest

50%

Examples:

  • Eli Lilly is moving into the drug supply chain but it's just an extension of their existing services and not a shift in business strategy as implied by the title of the article.

Contradictions

85%

Examples:

  • WW International Inc. plunged 11% after Eli Lilly launched a digital health-care platform to deliver weight-loss drugs which poses a threat to WW's key area of growth.

Deceptions

30%

Examples:

  • The author states that demand for Mounjaro has soared over the past two years without providing any evidence or data to support this claim. The title of the article implies weight loss drugs are available from Eli Lilly but only mentions one drug (Zepbound).

Recent Articles

Eli Lilly Launches New Service for Telehealth Prescriptions of Weight Loss Drugs

Eli Lilly Launches New Service for Telehealth Prescriptions of Weight Loss Drugs

Broke On: Friday, 05 January 2024 Eli Lilly has launched an online service called LillyDirect The platform allows patients to receive telehealth prescriptions and direct home delivery of certain medications for obesity, diabetes and migraines This marks a shift in the drug supply chain by a pharmaceutical company into the digital health-care space Some analysts view this move as an opportunity for Lilly to gain market share in weight loss solutions Others are concerned about its potential impact on traditional players like WeightWatchers and other companies that provide online access to prescription weight-loss drugs.